surmount-1 tirzepatide trial weight loss non-diabetic results SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes The results are finally in – Relationship of early rapid weight

These findings are consistent with prior studies that have documented the metabolic and cardiovascular benefits of arGLP-1, including reductions in glycated hemoglobin levels and blood pressure

To view or add a comment, sign in I have never had a paper accepted on its initial submission, but today the American Journal of Psychiatry accepted my paper with Steven Reidbord, M.D

Eligibility depends on factors such as: Current Wegovy dose and duration of use Weight-loss progress and overall health outcomes History of side effects or intolerance Other medical conditions (such as pancreatitis or gallbladder disease) Other medications being taken Switching should only be considered after a structured review with a doctor who understands your full medical history and treatment goals

[ClinicalTrials.gov] FDA